Literature DB >> 20303011

Genomic alterations of chromosome region 11p as predictive marker by array comparative genomic hybridization in lung adenocarcinoma patients.

Jae Sook Sung1, Kyong Hwa Park, Yeul Hong Kim.   

Abstract

Array comparative genomic hybridization (aCGH) provides a method to quantitatively measure the changes of DNA copy number with an extremely high resolution and to map them directly onto the complete linear genome sequences. In this study, we used aCGH to compare genomic alterations in fresh-frozen lung cancer tissues of 21 adenocarcinomas (AdCCs) (11 early relapse and 10 nonrelapse) and identified genomic alterations that showed significant by different frequency between early relapse and nonrelapse AdCCs. Twelve clones were identified by the false discovery rate (FDR) test, and Kaplan-Meier analyses were selected as predictive markers. The significant gain clones were found in 11p (11p15.4, 11p15.1, and 11p13). When the cutoff value was 2, study of the association between candidate clones and relapse prediction revealed that early relapse and nonrelapse groups were most effectively separated. To further validate the gain of chromosome 11p region that was identified by array CGH, fluorescence in situ hybridization (FISH) was performed. To further confirm the results of aCGH, copy number changes of cancer-related candidate genes in AdCC patients were compared by real-time quantitative polymerase chain reaction. Array CGH and real-time quantitative polymerase chain reaction data were found to correspond to delineated DNA copy number changes. Genomic alterations of chromosome 11p region in AdCC patients were observed with aCGH, and a relapsable marker was identified in the nonrelapse group. This marker could be useful in stratifying patient groups according to likelihood of relapse for adjuvant treatment after surgical resection. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20303011     DOI: 10.1016/j.cancergencyto.2009.12.001

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  5 in total

1.  TRAF6 is an amplified oncogene bridging the RAS and NF-κB pathways in human lung cancer.

Authors:  Daniel T Starczynowski; William W Lockwood; Sophie Deléhouzée; Raj Chari; Joanna Wegrzyn; Megan Fuller; Ming-Sound Tsao; Stephen Lam; Adi F Gazdar; Wan L Lam; Aly Karsan
Journal:  J Clin Invest       Date:  2011-09-12       Impact factor: 14.808

2.  Array-comparative genomic hybridization reveals loss of SOCS6 is associated with poor prognosis in primary lung squamous cell carcinoma.

Authors:  Krishna B Sriram; Jill E Larsen; Santiyagu M Savarimuthu Francis; Casey M Wright; Belinda E Clarke; Edwina E Duhig; Kevin M Brown; Nicholas K Hayward; Ian A Yang; Rayleen V Bowman; Kwun M Fong
Journal:  PLoS One       Date:  2012-02-17       Impact factor: 3.240

3.  Whole genome microarray analysis in non-small cell lung cancer.

Authors:  Mohammad Al Zeyadi; Ivanka Dimova; Vladislav Ranchich; Blaga Rukova; Desislava Nesheva; Zora Hamude; Sevdalin Georgiev; Danail Petrov; Draga Toncheva
Journal:  Biotechnol Biotechnol Equip       Date:  2015-01-19       Impact factor: 1.632

Review 4.  Prognostic factors in resected lung carcinomas.

Authors:  Keith M Kerr; Marianne C Nicolson
Journal:  EJC Suppl       Date:  2013-09

5.  Adjusting breast cancer patient prognosis with non-HER2-gene patterns on chromosome 17.

Authors:  Vassiliki Kotoula; Mattheos Bobos; Zoi Alexopoulou; Christos Papadimitriou; Kyriaki Papadopoulou; Elpida Charalambous; Eleftheria Tsolaki; Grigorios Xepapadakis; Irene Nicolaou; Irene Papaspirou; Gerasimos Aravantinos; Christos Christodoulou; Ioannis Efstratiou; Helen Gogas; George Fountzilas
Journal:  PLoS One       Date:  2014-08-06       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.